UNSPSC 51162649: Viminol

This classification denotes an ethanolamine antitussive and analgesic with the molecular formula C21H31ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) TPV54G6XBG, chemically known as 1h-pyrrole-2-methanol, alpha-((bis(1-methylpropyl)amino)methyl)-1-((2-chlorophenyl)methyl)- but more generally known as viminol, which bears US NIH Compound Identifier 65697. European Medicines Agency schedules Viminol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00050MIG.

UNSPSC 51162649 Viminol, a Commodity code, encompasses pharmaceutical and medical products that state and local governments procure for public health, emergency response, and community health initiatives. Recent solicitations show state and local bodies buying naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products through both direct purchase and cooperative purchasing frameworks. Issuing bodies include county health departments and state cooperative purchasing alliances that aggregate demand across multiple state and local government entities; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, acts as a centralized procurement vehicle for multi-jurisdictional pharmaceutical supply agreements.

Activity is concentrated in Florida and Minnesota as of mid-2026. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. MMCAP issued RFP S1070000015802 on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, including Oregon, with proposals due March 26, 2026; awarded vendors become available to authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. by May 15, 2026, with contract effective July 1, 2026. Both opportunities require vendors to comply with FDA requirements, maintain specified insurance coverage, and meet supply chain security standards; the MMCAP contract emphasizes cGMP and DSCSA compliance with a 3 percent administrative fee on all purchases.